Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Clinical trial NCT06582017 · RECRUITING

Trial details

NCT number: NCT06582017
Sponsor: Nammi Therapeutics Inc
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Ovarian Cancer Pancreas Cancer Urothelial Carcinoma Renal Cell Carcinoma Hepatocellular Carcinoma Gastrointestinal Cancer Lung Cancer Prostate Cancer Breast Cancer

Start date: 2024-08-28
Primary completion: 2027-12-31
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.